NewBiologix has announced it has granted a non-exclusive technology license to ReciBioPharm to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.
Antares Vision Group, has expanded its solutions portfolio to include precision labelling equipment, through a partnership with Italy-based Siempharma.
Astraveus, the benchtop cell factory company, has announced that it has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen).
Aptamer Group, a developer of next-generation synthetic binders, has announced the adaptation of the Optimer-based test for Alzheimer’s disease into an Enzyme-Linked Immunosorbent Assay (ELISA).
Aptar CSP Technologies, part of AptarGroup, has announced the expansion of its service offerings with the launch of a cGMP-compliant manufacturing facility in New Jersey.
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints.
PCI Pharma Services, a global contract development and manufacturing organisation (CDMO) focused on innovative biopharma therapies, has completed its acquisition of Ajinomoto Althea.
Identiv and InPlay, a wireless System-on-Chip (SoC) solution provider, has announced the co-development of a new portfolio of BLE-enabled smart labels designed for high-value logistics applications.
